Korro Bio, Inc. (KRRO) stock

KRRONasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30

$14.31−0.10 (-0.69%)

Close on Nov 12, 2026Market cap $210.72MP/E –Yield –

Korro Bio ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Korro Bio has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is KRRO.

Revenue growth-82.5% · median -93.5%

Operating margin-8467.3% · median -7903.6%

Net margin-8214.5% · median -6903.2%

Advertisement
300 × 250

See a number that looks wrong?